Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow Tucker

Eli Lilly India chief Winselow Tucker said the companys strategy of combining a strong product with ecosystem partnerships and patient education has helped drive early momentum for Mounjaro in India, where the dual-action diabetes and obesity drug has clocked ₹450 crore in sales within seven months. He said India has a large unmet need, with nearly 100 million people living with obesity and diabetes, and that tirzepatides dual GIP and GLP-1 mechanism has set it apart in both weight and glucose management.